Irregular protein clumps called fibrils accumulate in the heart, making it difficult for the heart to pump blood.

Image Credit : Google Image

The study achieved the primary endpoint of change from baseline on the 6-Minute Walk Test (6-MGT) at 12 months compared with placebo.

 The study also achieved its first secondary endpoint of change  in quality of life from baseline compared to placebo.

Patisiran also showed an encouraging safety and tolerability profile, with deaths numerically favoring the patisiran group. 

The company plans to submit additional regulatory applications to the FDA in the second half of 2022.  

Five patients (2.8%) in the patisiran group and eight (4.5%) in the placebo group died. Additionally,

the number of deaths in the all-cause  efficacy analysis was 4 (2.2%) in the patisiran group and 10 (5.6%) in the placebo group. 

 Adverse event rates were similar between the patisilan and placebo groups. 

Alnylam Pharma Stock Is Trading High In Premarket Sessions

 Patisiran is marketed as His Onpattro and is approved in the US and Canada for hATTR amyloidosis polyneuropathy in adults.

 Price Action: ALNY shares rose 55.8% to $220.00 during Wednesday's premarket session.

Alnylam Pharma Stock Is Trading High In Premarket Sessions